How much weight did STEP-2 participants with type 2 diabetes lose on semaglutide 2.4 mg?

Participants lost an average of 9.6% of body weight over 68 weeks, compared to 3.4% with placebo. Nearly half (45.6%) achieved ≥10% weight loss.

Did STEP-2 include patients on insulin?

No. The trial excluded patients using insulin. Participants were on 1-3 oral antidiabetic agents only. Clinicians extrapolating to insulin-treated patients should consider hypoglycemia risk and the need for insulin dose reduction.

What was the difference between semaglutide 2.4 mg and 1.0 mg in STEP-2?

The 2.4 mg dose produced 9.6% weight loss vs 7.0% with 1.0 mg, a 2.6 percentage-point difference. Both doses improved HbA1c similarly (−1.6 vs −1.5 points).

Did STEP-2 lead to guideline changes?

Yes. The 2022 ADA/EASD consensus report and 2023 ADA Standards of Care integrated weight-centric GLP-1 RA prescribing into the T2D treatment algorithm, citing STEP-2 as key evidence.

What were the main side effects in STEP-2?

Gastrointestinal events (nausea, diarrhea, vomiting) occurred in 63.5% of the 2.4 mg group. Nausea caused 4.5% of that group to discontinue treatment. Most GI events were mild to moderate and occurred during dose escalation.

Can semaglutide 2.4 mg be combined with SGLT2 inhibitors?

STEP-2 included patients on background SGLT2 inhibitors who achieved similar weight loss to the overall cohort. The combination appears safe and effective based on trial data.

Is semaglutide 2.4 mg FDA-approved for type 2 diabetes?

Semaglutide 2.4 mg (Wegovy) is approved for chronic weight management in adults with BMI ≥27 and at least one weight-related comorbidity, which includes T2D. However, semaglutide 1.0 mg (Ozempic) holds the specific T2D glycemic control indication.

How long does it take to reach the full 2.4 mg dose?

The protocol uses a 16-week titration: 0.25 mg for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each step lasting 4 weeks.

Does weight loss from semaglutide persist after stopping?

STEP-2 did not include a withdrawal phase. Other STEP program data (STEP-1 extension) showed significant weight regain after discontinuation, suggesting ongoing treatment is needed to maintain results.

Who should consider semaglutide 2.4 mg instead of 1.0 mg?

Patients with T2D whose primary treatment goal is weight reduction (not just glycemic control), those who have plateaued on 1.0 mg, and those with BMI ≥30 where greater weight loss would meaningfully reduce cardiovascular or metabolic risk.

What STEP-2 Actually Changes in Clinical Practice

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Parameter | Detail | |-----------|--------| | N | 1,210 adults with T2D and BMI ≥27 | | Intervention | Semaglutide 2.4 mg SC once weekly | | Comparator | Semaglutide 1.0 mg SC once weekly; placebo | | Duration | 68 weeks | | Primary endpoint | Percentage change in body weight from baseline | | Key result | −9.6% (2.4 mg) vs −7.0% (1.0 mg) vs −3.4% (placebo) |

Why weight loss is harder in type 2 diabetes

Patients with T2D consistently lose less weight than those without diabetes on identical interventions. The reasons are physiological, not behavioral. Insulin resistance promotes lipogenesis. Many glucose-lowering agents (sulfonylureas, insulin, thiazolidinediones) cause weight gain. Beta-cell compensation blunts the satiety signaling that GLP-1 agonists exploit. Prior trials of liraglutide 3.0 mg showed roughly 4-6% weight loss in T2D populations compared to 8% in non-diabetic cohorts.

STEP-1 had already demonstrated 12.4% weight loss in non-diabetic adults. The open question was whether semaglutide 2.4 mg could overcome the diabetes weight-loss penalty. STEP-2 answered that directly.

Methodology notes clinicians should actually read

The STEP-2 protocol enrolled adults aged 18+ with BMI ≥27, HbA1c 7-10%, and T2D diagnosed at least 180 days before screening. Participants were on stable oral antidiabetic therapy (metformin, sulfonylureas, SGLT2 inhibitors, or combinations). Insulin users were excluded. This matters because the trial population represents early-to-mid T2D, not advanced disease requiring complex regimens.

The dose-escalation schedule followed the standard 16-week titration to 2.4 mg. The trial included a third arm at 1.0 mg (the Ozempic dose approved for glycemic control) specifically to isolate the incremental benefit of the higher dose for weight.

Lifestyle intervention was standardized: 150 minutes of physical activity weekly plus a 500 kcal/day deficit. Both active arms and placebo received identical counseling. The trial used a treatment-policy estimand (intention to treat regardless of adherence) as the primary analysis, which makes results conservative.

The HealthRX Practice-Change Framework for STEP-2

We assess trial impact across four dimensions: guideline uptake, formulary access, prescribing behavior shift, and patient-selection refinement. Here is where STEP-2 lands on each.

1. Guideline uptake

The 2022 ADA/EASD consensus report on managing hyperglycemia in T2D was the first major document to explicitly recommend GLP-1 RAs with proven weight-management efficacy for patients with T2D and obesity, citing STEP-2. Previously, weight management and glucose management were treated as parallel goals with different drug hierarchies. Post-STEP-2, the ADA Standards of Care (2023 revision) integrated weight-centric prescribing into the T2D algorithm rather than reserving it for a separate obesity section.

The 2023 AAP/AGA/Endocrine Society guidelines on pharmacotherapy for obesity also cited STEP-2 when extending semaglutide 2.4 mg recommendations to patients with T2D, noting the trial's demonstration that glycemic benefit was additive to existing oral agents.

2. Formulary and access shifts

Before STEP-2, insurers could reasonably argue that semaglutide 1.0 mg (Ozempic) addressed both glycemic control and modest weight loss in T2D, making the 2.4 mg dose (Wegovy) redundant. STEP-2 dismantled that argument by showing the 2.4 mg dose produced 2.6 percentage points more weight loss than 1.0 mg in the same population. The absolute difference (roughly 6 kg) crosses the threshold most payers define as clinically distinct.

By 2024, several large pharmacy benefit managers began covering Wegovy for patients with T2D and BMI ≥27 who had not reached weight goals on Ozempic alone. This was a direct consequence of STEP-2's three-arm design proving dose-dependent benefit.

3. Prescribing behavior shift

Before STEP-2, most endocrinologists prescribed semaglutide 1.0 mg for T2D and referred separately to obesity medicine if weight remained a problem. After STEP-2, a growing cohort of prescribers initiate at 2.4 mg when the primary goal is weight reduction in a patient who also has T2D. The distinction matters for FDA labeling: Wegovy's indication is chronic weight management, while Ozempic's is glycemic control. Same molecule, different regulatory lanes.

4. Patient-selection refinement

STEP-2 enrolled patients on 1-3 oral agents with HbA1c 7-10%. Subgroup analyses showed consistent weight loss across baseline HbA1c strata, BMI categories, and background medications. Patients on SGLT2 inhibitors at baseline still achieved ~9% loss. Those on sulfonylureas had marginally higher rates of hypoglycemia (both documented and symptomatic) but similar weight outcomes.

The practical takeaway: clinicians do not need to discontinue SGLT2 inhibitors before adding semaglutide 2.4 mg. However, sulfonylurea dose reduction at initiation is prudent.

Result details beyond the headline

| Outcome | Semaglutide 2.4 mg | Semaglutide 1.0 mg | Placebo | |---------|--------------------|--------------------|---------| | Mean weight change (%) | −9.6 | −7.0 | −3.4 | | ≥5% weight loss (%) | 68.8 | 57.1 | 28.5 | | ≥10% weight loss (%) | 45.6 | 28.7 | 8.2 | | ≥15% weight loss (%) | 25.8 | 13.7 | 3.2 | | HbA1c change (%-points) | −1.6 | −1.5 | −0.4 | | Proportion reaching HbA1c <7% | 78.6 | 72.3 | 36.6 |

Source: Davies et al., Lancet 2021

The dual benefit is striking. Patients achieved both weight targets and glycemic targets simultaneously. Nearly 46% of the 2.4 mg group lost ≥10% body weight, a threshold associated with T2D remission in shorter-duration disease.

Limitations the authors acknowledged

The trial excluded patients on insulin. This is a large population (roughly 25-30% of T2D patients in primary care). Whether semaglutide 2.4 mg produces similar weight loss in insulin-treated patients remained uncertain until later data emerged.

Duration was 68 weeks. Weight regain after GLP-1 RA discontinuation is well documented. STEP-2 did not include a withdrawal phase, so durability of weight loss off-treatment was not assessed within this trial.

The population was predominantly White (61%) and from high-income countries. Generalizability to populations with different metabolic phenotypes (e.g., South Asian patients with lower BMI but higher visceral adiposity) requires caution.

Gastrointestinal adverse events occurred in 63.5% of the 2.4 mg group vs 34.3% placebo. Nausea led to discontinuation in 4.5% of the high-dose arm. In clinical practice, slower titration or anti-emetic support may improve retention beyond what the protocol-driven schedule achieved.

What this means for patients who differ from the trial population

Patients on insulin: The STEP-5 extension and real-world registry data suggest benefit persists, but hypoglycemia management is more complex. Basal insulin dose reduction of 10-20% at semaglutide initiation is common practice.

BMI 25-27 with T2D: STEP-2 required BMI ≥27. Asian patients with T2D and BMI 25-27 represent a gap. The 2023 ADA Standards now use ethnicity-adjusted BMI thresholds, partially addressing this.

Patients already on semaglutide 1.0 mg: STEP-2's three-arm design gives direct evidence for dose escalation. The incremental 2.6% weight loss from 1.0 to 2.4 mg justifies uptitration in patients who plateau.

Older adults (>65): The trial included patients up to age 75. Subgroup data showed consistent efficacy but slightly higher GI discontinuation rates in those over 65. Sarcopenia risk from rapid weight loss in older adults remains a clinical concern not addressed by the trial design.

The bottom line for prescribers

STEP-2 converted semaglutide 2.4 mg from an obesity drug that happened to lower glucose into a legitimate dual-purpose therapy for the T2D-obesity phenotype. The trial's most important practical contribution was not the 9.6% weight loss number itself. It was proving that the diabetes weight-loss penalty could be substantially overcome with adequate GLP-1 RA dosing, and that glycemic improvement came along without additional glucose-lowering agents.

Clinicians who still prescribe semaglutide 1.0 mg as a ceiling dose for T2D patients with obesity are leaving measurable benefit on the table. STEP-2 says the dose-response curve has not flattened at 1.0 mg.

Frequently asked questions

›

References

Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. https://pubmed.ncbi.nlm.nih.gov/33667417/
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
FDA. Wegovy (semaglutide) prescribing information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786. https://pubmed.ncbi.nlm.nih.gov/36202135/
Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT). Lancet. 2018;391(10120):541-551. https://pubmed.ncbi.nlm.nih.gov/29127694/